The European Commission has adopted a package of infringement decisions due to Member States failing to communicate measures taken to transpose EU directives into national law.
As of 1 July 2024, significant changes have been implemented regarding the declaration of pharmaceutical products (medicines) and active substances for import.
Met ingang van 1 juli 2024 zijn er belangrijke wijzigingen doorgevoerd met betrekking tot de aangifte van farmaceutische producten (geneesmiddelen) en werkzame stoffen voor import.
Voor deze pakketjes geldt momenteel een douanevrijstelling, waardoor er geen importheffingen zijn verschuldigd bij binnenkomst in de EU. De Europese commissie is nu voornemens om deze vrijstelling te laten vervallen.
These cheap goods are currently subject to a customs exemption, meaning that no import duties are due when entering the EU. The European commission is now planning to remove this exemption.
Vanaf 29 oktober 2024 verandert er iets in het proces douanevervoer. Vanaf dan gebruikt u niet meer het aangiftesysteem New Computerized Transit System (NCTS fase 4), maar de Douane Vervoer Applicatie (NCTS fase 5).
As of October 29, 2024, there will be a change in the customs transit process. From that date, you will no longer use the declaration system New Computerized Transit System (NCTS phase 4), but the Customs Transport Application (NCTS phase 5).
In October 2023, the transitional period for the Carbon Border Adjustment Mechanism (CBAM) began. This period, which runs from October 1, 2023, to December 31, 2025, offers companies the opportunity to adapt to the new situation, become familiar with the system, and prepare for the collection of accurate data.
Starting from September 2024, companies submitting customs declarations will receive a monthly specification with the Notice of Payment Deadline (MAB).
Vanaf september 2024 zullen bedrijven die douaneaangiftes doen, maandelijks een specificatie ontvangen bij de Mededeling Afloop Betalingstermijn (MAB).
